EFMC: Trends in Medicinal Chemistry and Chemical Biology
ChemBioChem · 2023
DOI: 10.1002/cbic.202200690 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemBioChem, 2023. Verfasst von Yves P Auberson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Novartis Institutes for BioMedical Research Novartis Campus - WSJ-88.10, 4056, Basel, Switzerland. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Drug Discovery. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 275 Literaturangaben.
Abstract (Originalsprache)
Ground‐breaking research in disease biology and continuous efforts in method development have uncovered a range of potential new drug targets. Increasingly, the drug discovery process is informed by technologies involving chemical probes as tools. Applications for chemical probes comprise target identification and assessment, as well as the qualification of small molecules as chemical starting points and drug candidates. Progress in probe chemistry has opened the way to novel assay formats and pharmaceutical compound classes. The European Federation of Medicinal Chemistry and Chemical Biology (EFMC) has launched the Chemical Biology Initiative to advance science in the field of medicinal chemistry and chemical biology, while representing all members of this extended scientific community. This review provides an overview of the many important developments in the field of chemical biology that have happened at the lively interface of academic and industrial research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research Novartis Campus - WSJ-88.10, 4056, Basel, Switzerland.
- Department Epigenetic Chemical Biology, Institut Pasteur, Université de Paris CNRS UMR3523 Chem4Life, 28 rue du Dr Roux, 75015, Paris, France.
- Université Côte d'Azur Institut de Chimie de Nice (ICN), UMR7272 CNRS Parc Valrose, 06100, Nice, France.
- Bayer AG, Research & Development, Pharmaceuticals, Drug Discovery Sciences, Life Science Technologies Aprather Weg 18a, Gebäude 460, Raum 345, 42113, Wuppertal, Germany.
- F. Hoffmann-La Roche Ltd. Pharma Research and Early Development, pRED, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.
- Epigenetic Med Chem Lab, Department of Pharmacy, University of Salerno via Giovanni Paolo II 132, 84084, Fisciano (SA), Italy.
ORCID-Profile: Yves P Auberson
Zitieren
APA
Auberson, Y. P., Arimondo, P. B., Duca, M., Essig, S., Grether, U., Rufer, A. C., Sbardella, G., Schopfer, U., Torrens, A., van der Stelt, M., Vauzeilles, B., Vázquez, O., & Zhang, A. X. (2023). EFMC: Trends in Medicinal Chemistry and Chemical Biology. ChemBioChem. https://doi.org/10.1002/cbic.202200690
Vancouver
Auberson YP, Arimondo PB, Duca M, Essig S, Grether U, Rufer AC, et al. EFMC: Trends in Medicinal Chemistry and Chemical Biology. ChemBioChem. 2023. doi:10.1002/cbic.202200690
BibTeX
@article{Auberson2023,
author = {Auberson, Yves P and Arimondo, Paola B and Duca, Maria and Essig, Sebastian and Grether, Uwe and Rufer, Arne C and Sbardella, Gianluca and Schopfer, Ulrich and Torrens, Antoni and van der Stelt, Mario and Vauzeilles, Boris and Vázquez, Olalla and Zhang, Andrew X},
title = {EFMC: Trends in Medicinal Chemistry and Chemical Biology},
journal = {ChemBioChem},
year = {2023},
doi = {10.1002/cbic.202200690}
}
EUVIMED